• Revenue A$9,645 million, up 8%
• EBITDA A$1,725 million, up 8%
• Net profit A$514 million, up 7%

Sonic Healthcare Limited has reported its financial results for the year ended 30 June 2025. The company achieved revenue of A$9,645 million, up 8% from the prior year, and EBITDA of A$1,725 million, up 8%. Net profit attributable to Sonic shareholders was A$514 million, up 7%. The company's full-year guidance range was achieved, with EBITDA of A$1,702 million on a Constant Currency basis (A$1,730 million after adjusting for non-recurring items). Organic revenue growth was 5%, and the company saw normalised EBITDA margin expansion of 40 basis points. The growth was driven by organic revenue growth and cost efficiency programs. Synergy initiatives from acquisitions completed in FY2024 and FY2025 are on track, with the majority of benefits to be realised in FY2026 and FY2027. The company's cash generated from operations was 21% higher than the prior year due to a 48% reduction in income taxes paid. Sonic expects EBITDA for FY2026 in the range of A$1.87 to A$1.95 billion on a Constant Currency basis, representing up to ~13% growth on FY2025 EBITDA.

Sonic expects EBITDA for FY2026 in the range of A$1.87 to A$1.95 billion on a Constant Currency basis, representing up to ~13% growth on FY2025 EBITDA. Depreciation (including of leased assets) is expected to be a similar percentage of revenue in FY2026 as in FY2025. Net interest expense is expected to increase by 15 to 20% from the FY2025 level (on a Constant Currency basis), due to the business acquisitions in FY2026. The effective tax rate is expected to be ~27%.

Sonic is expecting strong FY2026 earnings growth driven by organic growth, Swiss and German synergies, the LADR acquisition, and initiatives in the US market.